BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 23265189)

  • 1. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory agents in myelofibrosis.
    Tabarroki A; Tiu RV
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1141-54. PubMed ID: 22668122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.
    Gay F; Mina R; Troia R; Bringhen S
    Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1517-27. PubMed ID: 23961770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
    Shortt J; Hsu AK; Johnstone RW
    Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide therapy for myeloma.
    Schey S; Ramasamy K
    Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.
    Ocio EM; Mateos MV; San-Miguel JF
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1075-87. PubMed ID: 22621161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
    Mark TM; Coleman M; Niesvizky R
    Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pomalidomide for multiple myeloma].
    Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
    Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging biological insights and novel treatment strategies in multiple myeloma.
    Gentile M; Recchia AG; Mazzone C; Morabito F
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
    Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel generation of agents with proven clinical activity in multiple myeloma.
    Mateos MV; Ocio EM; San Miguel JF
    Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
    Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
    Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New immunomodulatory drugs in myeloma.
    Lacy MQ
    Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.